DEA Targets New Synthetic Drug for Schedule I Ban
Published Date: 10/2/2025
Proposed Rule
Summary
The DEA wants to officially put MDMB-4en-PINACA, a powerful drug, into Schedule I, meaning it’s illegal to make, sell, or use. This move helps the U.S. follow international drug rules and keeps strict penalties for anyone caught handling it. If approved, these rules will stay in place permanently, affecting manufacturers, researchers, and users right away.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Possession and Handling Made Illegal
If finalized, MDMB-4en-PINACA would be placed in Schedule I. That would make it illegal to manufacture, distribute, import, export, or possess MDMB-4en-PINACA, and the existing Schedule I regulatory controls plus civil, administrative, and criminal sanctions would apply to people who handle it.
Researchers Subject to Schedule I Controls
If finalized, people who 'engage in research, conduct instructional activities or chemical analysis' with MDMB-4en-PINACA would be covered by the same Schedule I regulatory controls and civil, administrative, and criminal sanctions as other Schedule I substances.
Manufacturers and Traders Face Permanent Controls
If finalized, MDMB-4en-PINACA would be placed in Schedule I and the rule would make permanent the existing regulatory controls and civil, administrative, and criminal sanctions that apply to manufacture, distribution, importation, and export of Schedule I substances.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-19280, Visibility Protection: Regional Haze State Plan Requirements Rule Revision
The EPA wants to make it easier for states to protect clear skies in special natural areas by updating the rules they follow. States that manage air quality near these spots will see changes in how they plan and report their progress. The EPA is asking for ideas now, so expect new rules and deadlines soon that could save time and money.
Next: 2025-19363, Fishery Management Plans of St. Croix and St. Thomas and St. John; Queen Triggerfish Management Measures
Fishermen and seafood lovers around St. Croix, St. Thomas, and St. John, listen up! New rules are coming to adjust how many queen triggerfish can be caught each year to keep the fish population healthy and strong. These changes, based on fresh science, aim to stop overfishing and make sure there’s plenty of fish for the future—starting as soon as the rule is official.